Sana Biotechnology (NASDAQ:SANA) Trading 7.7% Higher – What’s Next?

Sana Biotechnology, Inc. (NASDAQ:SANA)’s share price traded up 7.7% during mid-day trading on Monday . The stock traded as high as $4.07 and last traded at $4.05. 165,429 shares were traded during trading, a decline of 92% from the average session volume of 2,168,752 shares. The stock had previously closed at $3.76.

Analyst Ratings Changes

SANA has been the topic of a number of research reports. Citigroup increased their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright cut their price target on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, August 9th.

Sana Biotechnology Trading Down 3.6 %

The company has a fifty day moving average of $4.59 and a two-hundred day moving average of $6.03. The stock has a market capitalization of $840.94 million, a price-to-earnings ratio of -3.29 and a beta of 1.42.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). As a group, sell-side analysts predict that Sana Biotechnology, Inc. will post -1.13 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the transaction, the director now owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. grew its position in Sana Biotechnology by 1,246.6% in the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after purchasing an additional 12,154 shares during the last quarter. Algert Global LLC acquired a new stake in Sana Biotechnology during the second quarter worth about $73,000. Hartline Investment Corp bought a new position in Sana Biotechnology during the first quarter valued at about $136,000. XTX Topco Ltd acquired a new position in Sana Biotechnology in the 2nd quarter valued at approximately $100,000. Finally, Dark Forest Capital Management LP lifted its position in shares of Sana Biotechnology by 112.0% in the 2nd quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock worth $149,000 after acquiring an additional 14,430 shares during the period. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.